A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of Atezolizumab (Mpdl3280a, Anti-Pd-L1 Antibody) In Combinat
Posted Date: May 15, 2019
- Investigator: John Morris
- Type of Study: Drug
The purpose of this study is to look at the effects, good or bad, of atezolizumab on you and the specific type of lung cancer (non-small cell lung cancer [NSCLC]) you have. Atezolizumab is an experimental drug, which means that health authorities have not approved atezolizumab for the treatment of
Criteria:
To Be Eligible To Participate, Patients Must Have Been Diagnosed With Stage Iv Squamous Non-Small Ce
Keywords:
Cancer, Go29437, Lung, Non Small Cell, Non Squamous
For More Information:
Uc Cancer Center
513-584-7698
kastla@uc.edu